• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Aura Biosciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    6/21/24 4:07:00 PM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $AURA alert in real time by email
    8-K
    false 0001501796 --12-31 0001501796 2024-06-20 2024-06-20

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): June 20, 2024

     

     

    Aura Biosciences, Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

     

    Delaware   001-40971   32-0271970

    (State or Other Jurisdiction

    of Incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

    80 Guest Street  
    Boston, Massachusetts     02135
    (Address of Principal Executive Offices)     (Zip Code)

    Registrant’s Telephone Number, Including Area Code: 617 500-8864

    Not Applicable

    (Former Name or Former Address, if Changed Since Last Report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading

    Symbol(s)

     

    Name of each exchange

    on which registered

    Common Stock, $0.00001 par value per share   AURA   The Nasdaq Global Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     


    Item 5.03.

    Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

    On June 20, 2024, Aura Biosciences, Inc. (the “Company”) held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”). As further described below in Item 5.07 to this Current Report on Form 8-K, at the Annual Meeting, the Company’s stockholders approved an amendment to the Company’s Tenth Amended and Restated Certificate of Incorporation (the “Charter Amendment”) to limit the liability of certain officers of the Company as permitted by the Delaware General Corporation Law (“DGCL”). A description of the Charter Amendment is set forth in the Company’s definitive proxy statement (the “Proxy Statement”) filed with the Securities and Exchange Commission (the “SEC”) on April 25, 2024 under Section 14(a) of the Securities Exchange Act of 1934, as amended, in the section titled “Proposal No. 2 – Approval of Amendment to Tenth Amended and Restated Certificate of Incorporation to Reflect Delaware General Corporation Law Provisions Regarding Exculpation of Officers.” The Charter Amendment was previously approved by the Company’s Board of Directors (the “Board”), subject to approval by the Company’s stockholders.

    On June 20, 2024, the Company filed the Charter Amendment with the Secretary of State of the State of Delaware and the Charter Amendment became effective upon filing.

    The foregoing description of the Charter Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Charter Amendment, a copy of which is filed as Exhibit 3.1 to this Current Report on Form 8-K and incorporated herein by reference.

     

    Item 5.07.

    Submission of Matters to a Vote of Security Holders.

    The proposals set forth below were submitted to the stockholders at the Annual Meeting held on June 20, 2024, with each such proposal described in the Proxy Statement for the Annual Meeting filed with the SEC on April 25, 2024, and the supplement to the Proxy Statement filed with the SEC on June 14, 2024.

    The number of shares of common stock entitled to vote at the Annual Meeting was 49,533,018. The number of shares of common stock present or represented by valid proxy at the Annual Meeting was 38,742,131. The number of votes cast for and against and the number of abstentions and broker non-votes with respect to each proposal voted upon at the Annual Meeting are set forth below.

    Proposal 1 - Election of Directors

    The Company’s stockholders elected the two (2) director nominees below to the Board as Class III directors to hold office until the 2027 Annual Meeting of Stockholders of the Company or until their successors are duly elected and qualified.

     

    Director Nominee

       Votes For      Votes Withheld      Broker Non-Votes  

    Antony Mattessich

         28,299,345        4,803,231        5,639,555  

    Sapna Srivastava, Ph.D.

         31,894,914        1,207,662        5,639,555  

    Proposal 2 – Approve an Amendment to the Company’s Tenth Amended and Restated Certificate of Incorporation to reflect Delaware General Corporation Law Provisions regarding Exculpation of Officers

    The Company’s stockholders approved the Charter Amendment to limit the liability of certain officers of the Company as permitted by the DGCL.

     

    Votes For   Votes Against   Abstentions   Broker Non-Votes
    31,222,608   1,699,497   180,471   5,639,555

    Proposal 3 - Ratification of Appointment of Independent Registered Accounting Firm

    The Company’s stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2024.

     

    Votes For   Votes Against   Abstentions
    38,734,848   5,843   1,440


    Item 9.01.

    Financial Statements and Exhibits.

    (d) Exhibits.

     

    Exhibit

    No.

       Description
    3.1    Certificate of Amendment to Tenth Amended and Restated Certificate of Incorporation of the Registrant.
    104    Cover Page Interactive Data File (embedded within the Inline XBRL document).


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

          Aura Biosciences, Inc.
    Date: June 21, 2024     By:  

    /s/ Julie Feder

          Julie Feder
          Chief Financial Officer
    Get the next $AURA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AURA

    DatePrice TargetRatingAnalyst
    11/26/2025$13.00Outperform
    Evercore ISI
    5/28/2025$22.00Buy
    H.C. Wainwright
    7/25/2024$21.00Buy
    H.C. Wainwright
    7/27/2023Sector Outperform
    Scotiabank
    4/17/2023$38.00Buy
    BTIG Research
    7/19/2022$26.00Mkt Outperform
    JMP Securities
    11/24/2021$40.00Outperform
    SVB Leerink
    11/23/2021$38.00Buy
    BTIG Research
    More analyst ratings

    $AURA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Kilroy Conor

    4 - Aura Biosciences, Inc. (0001501796) (Issuer)

    4/16/26 6:49:19 PM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Officer De Los Pinos Elisabet was granted 166,000 shares, increasing direct ownership by 41% to 575,815 units (SEC Form 4)

    4 - Aura Biosciences, Inc. (0001501796) (Issuer)

    3/3/26 4:06:13 PM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Officer Gibney Anthony S was granted 71,245 shares, increasing direct ownership by 34% to 278,178 units (SEC Form 4)

    4 - Aura Biosciences, Inc. (0001501796) (Issuer)

    3/3/26 4:06:39 PM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AURA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Evercore ISI resumed coverage on Aura Biosciences with a new price target

    Evercore ISI resumed coverage of Aura Biosciences with a rating of Outperform and set a new price target of $13.00

    11/26/25 8:36:10 AM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright resumed coverage on Aura Biosciences with a new price target

    H.C. Wainwright resumed coverage of Aura Biosciences with a rating of Buy and set a new price target of $22.00

    5/28/25 9:07:05 AM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright initiated coverage on Aura Biosciences with a new price target

    H.C. Wainwright initiated coverage of Aura Biosciences with a rating of Buy and set a new price target of $21.00

    7/25/24 6:16:56 AM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AURA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Aura Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

    Accelerated Phase 3 CoMpass Enrollment Supports Mid-2026 Enrollment Completion and 2H 2027 Topline Data Guidance Phase 1b/2 NMIBC Trial on Track: Initial 3-Month Clinical Data Expected Mid-2026 12-month Stability Completed with New Formulation with Potential Across Non-ocular Solid Tumor Indications, Beginning with Urologic Oncology BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today reported financial results for the fourth quarter and year ended December 31, 2025, and provided recent business highlights. "2025 has been a year

    3/30/26 7:00:00 AM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Aura Biosciences to Participate in Upcoming Investor Conferences

    BOSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that members of its senior management team will participate in the following upcoming investor conferences: TD Cowen 46th Annual Health Care Conference on Wednesday, March 4, 2026. Fireside Chat at 9:10 a.m. ET. Leerink Partners Global Healthcare Conference on Tuesday, March 10, 2026. Fireside Chat at 3:40 p.m. ET. The Citizens Life Sciences Conference on Wednesday, March 11, 2026. Fireside Chat at 11:20 a.m. ET. The live webcasts of the fireside chats will be available

    2/25/26 7:00:00 AM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Aura Biosciences to Participate in the 8th Annual Evercore Healthcare Conference

    BOSTON, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025, at 10:50 a.m. ET. The live webcast of the fireside chat will be available on the "Investors & Media" page under the "Events & Presentations" section of the Company's website at https://ir.aurabiosciences.com/events-and-presentations, where a replay of the webcast will be archived for 90 days following t

    11/24/25 4:05:00 PM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AURA
    SEC Filings

    View All

    SEC Form S-8 filed by Aura Biosciences Inc.

    S-8 - Aura Biosciences, Inc. (0001501796) (Filer)

    3/30/26 7:27:38 AM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by Aura Biosciences Inc.

    10-K - Aura Biosciences, Inc. (0001501796) (Filer)

    3/30/26 7:15:29 AM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Aura Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

    8-K - Aura Biosciences, Inc. (0001501796) (Filer)

    3/30/26 7:05:19 AM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AURA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Johnson David Michael bought $98,000 worth of shares (20,000 units at $4.90), increasing direct ownership by 14% to 166,167 units (SEC Form 4)

    4 - Aura Biosciences, Inc. (0001501796) (Issuer)

    5/20/25 5:43:51 PM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Officer Gibney Anthony S bought $245,000 worth of shares (50,000 units at $4.90) and sold $7,823 worth of shares (1,519 units at $5.15), increasing direct ownership by 574% to 56,933 units (SEC Form 4)

    4 - Aura Biosciences, Inc. (0001501796) (Issuer)

    5/20/25 5:34:24 PM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Johnson David Michael bought $1,434,987 worth of shares (199,601 units at $7.19), increasing direct ownership by 171% to 135,667 units (SEC Form 4)

    4 - Aura Biosciences, Inc. (0001501796) (Issuer)

    11/9/23 5:02:28 PM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AURA
    Leadership Updates

    Live Leadership Updates

    View All

    NovaBridge's Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 Forward

    Cadmus C. Rich, MD, MBA, as Chief Medical Officer, and Carlos Quezada-Ruiz, MD, FASRS, as Chair of the Scientific Advisory Board, bring invaluable clinical development expertise to VIS-101 ProgramThe ability to attract seasoned ophthalmology leaders highlights the compelling opportunity for VIS-101, and underscores our commitment to assembling a world-class teamVIS-101, a novel bifunctional biologic targeting VEGF-A/ANG2, has the potential to become the current standard for wet AMD, DME and RVO, and is expected to be Phase-3-ready in 2026 ROCKVILLE, Md., Nov. 20, 2025 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (NASDAQ:NBP) (NovaBridge or the Company) a global biotechnology platform compa

    11/20/25 8:00:00 PM ET
    $AURA
    $FDMT
    $NBP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Aura Biosciences Announces Appointment of Teresa Bitetti to Board of Directors

    BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the appointment of Teresa Bitetti, President of the Global Oncology Business Unit at Takeda, to the Company's Board of Directors, effective March 31, 2025. "I am pleased to welcome Teresa to our Board of Directors," said Elisabet de los Pinos, Chief Executive Officer of Aura Biosciences. "She is a seasoned leader whose extensive operational and commercial experience will be instrumental as we advance our clinical pipeline across ocular and urologic oncology." "I am excit

    4/2/25 7:00:00 AM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Aura Biosciences Reports First Quarter 2024 Financial Results and Business Highlights

    Continued Enrollment in Global Phase 3 CoMpass Trial in Small Choroidal Melanoma and Indeterminate Lesions Ongoing Phase 1 Trial in Bladder Cancer Enrolling; Early Data Expected Mid-2024 Strong Cash Position Expected to Fund Operations into Second Half of 2026 BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors designed to preserve the function of the organ with cancer, today reported financial results for the first quarter ended March 31, 2024, and provided recent business highlights. "Throughout the first quarter of 2024, the Company made significant progress

    5/9/24 7:00:00 AM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AURA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Aura Biosciences Inc.

    SC 13G/A - Aura Biosciences, Inc. (0001501796) (Subject)

    11/14/24 5:50:51 PM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Aura Biosciences Inc.

    SC 13G/A - Aura Biosciences, Inc. (0001501796) (Subject)

    11/14/24 4:18:22 PM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Aura Biosciences Inc.

    SC 13G/A - Aura Biosciences, Inc. (0001501796) (Subject)

    11/12/24 9:32:49 AM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care